Metabolic effects of the triphasic oral contraceptive Trigynon.
Effects of Trigynon, a triphase low-dose oral contraceptive, containing ethinylestradiol and l-norgestrel in various proportions, on testosterone binding globulin, transcortin, thyroxine, free testosterone, free cortisol and free thyroxine as well as on plasma lipids and glucose tolerance were studied in 12 normal women treated for 3-6 months. Trigynon appears to have dominant estrogenic effects as evidenced from the increase in transport proteins and the decrease in free testosterone concentration. Plasma lipids were not significantly influenced; glucose tolerance was slightly, but not significantly decreased.
D000328:Adult; D001786:Blood Glucose / Q000032:analysis* / Q000378:metabolism; D050260:Carbohydrate Metabolism; D002784:Cholesterol / Q000097:blood; D003280:Contraceptives, Oral, Synthetic; D004997:Ethinyl Estradiol / Q000494:pharmacology*; D019304:Ethinyl Estradiol-Norgestrel Combination; D005260:Female; D006728:Hormones / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood*; D009644:Norgestrel / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D003280:Contraceptives, Oral, Synthetic; D006728:Hormones; D007328:Insulin; D008055:Lipids; D014280:Triglycerides; D009644:Norgestrel; D004997:Ethinyl Estradiol; D019304:Ethinyl Estradiol-Norgestrel Combination; D002784:Cholesterol